8-K filed Nov 12, 2026 at 16:43 ET
Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76 per share), compared to $5.4 million revenue and a $7.4 million loss in Q3 2025. The wider loss reflects a $35 million upfront payment to Innovent for in-licensing SP001, a Phase 2-ready anti-CD40L antibody for IgG4-related disease. Cash of $107.9 million funds operations into H2 2029, and the company has shifted focus from tebipenem HBr (now partnered with GSK) to immune-mediated diseases.